// App-Quantinova.ai

SAT0209 (2018) : A comparative real-world utilization patterns of innovator and biosimilar infliximab in a treatment naÏve and switch population from germany: a prescription claims analysis

Researchers

Presenter

  • E. M. Ewara

Principal Investigators

  • L. Ellis

  • K. Goyal

  • V. Jairath

  • A. M. Marrache

  • X. Baraliakos

Medical Centers

  • Government Affairs and Market Access, Janssen Inc., Toronto, Canada

  • Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, United States

  • Western University and London Health Sciences Centre, London, ON, CA

  • Medical Affairs, Janssen Inc., Toronto, ON, Canada

  • Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

Locations

  • Canada

  • United States

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab

  • Infliximab Biosimilar

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved